Immuneering CORP Form 4 insider transactions

Immuneering Corp's Chief Scientific Officer, Brett Matthew Hall, acquired 14,880 shares of Class A Common Stock through the company's Employee Stock Purchase Plan at $1.428 per share.

Immuneering Corp. Director Diana Hausman acquired 5,500 shares of Class A Common Stock through open market purchases, signaling increased insider confidence.

Immuneering Corp's Chief People Officer, Leah R. Neufeld, acquired 700 shares of Class A Common Stock at a price of $3.5695 per share, increasing her direct beneficial ownership to 10,729 shares.

Immuneering Corp's President and CEO, Benjamin J. Zeskind, has increased his direct beneficial ownership in the company through two open market purchases of Class A Common Stock in early July 2025.

Immuneering Corp. Director Thomas J. Schall purchased 9,500 shares of Class A Common Stock for approximately $34,788, increasing his beneficial ownership to 52,885 shares.

Immuneering Corp's Chief Scientific Officer, Brett Matthew Hall, has reported two recent open market purchases of Class A Common Stock, increasing his beneficial ownership in the company.

Immuneering Corp.'s Chief Business Officer, Harold Eugene Brakewood, increased his stake in the company by purchasing 1,900 shares of Class A Common Stock.

Immuneering Corp. Director and 10% Owner Peter Feinberg has increased his beneficial ownership in the company by purchasing 25,000 shares of Class A Common Stock.

Immuneering Corp's President and CEO, Benjamin J. Zeskind, has increased his direct beneficial ownership in the company by purchasing 21,000 shares of Class A Common Stock.

Immuneering Corp. Director Thomas J. Schall has acquired 40,485 shares of Class A Common Stock at a weighted average price of $2.2052 per share, increasing his beneficial ownership to 43,385 shares.

Immuneering Corp Director Diana Hausman was granted 33,350 stock options with an exercise price of $1.90, vesting over one year.

Immuneering Corp. director Thomas J. Schall was granted 33,350 stock options with an exercise price of $1.90 per share, vesting over one year.

Immuneering Corp. Director Laurie Keating was granted 33,350 stock options with an exercise price of $1.90, vesting over a one-year period.

Immuneering Corp. Director Peter Feinberg was granted 33,350 stock options with an exercise price of $1.90, vesting over a one-year period.

Immuneering Corp Director Robert J. Carpenter has been granted 33,350 stock options with an exercise price of $1.90, aligning his interests with shareholder value.

Immuneering Corp Director Ann E. Berman was granted 33,350 stock options with an exercise price of $1.90, vesting over one year starting July 13, 2025.

Igor Matushansky, Chief Medical Officer of Immuneering Corp, reports the acquisition of stock options.

Mallory Morales, Chief Accounting Officer of Immuneering Corp, was granted stock options for 110,000 shares on February 5, 2025.

Leah R. Neufeld, Chief People Officer of Immuneering Corp, reports the acquisition of stock options.

Harold Eugene Brakewood, Chief Business Officer of Immuneering Corp, reports the acquisition of 100,000 stock options.

Brett Matthew Hall, Chief Scientific Officer of Immuneering Corp, reports acquiring 240,000 stock options on February 5, 2025.

Immuneering Corp's CEO, Benjamin J. Zeskind, reports the acquisition of 480,000 stock options with an exercise price of $1.91, vesting monthly over four years.

Michael Bookman, Chief Legal Officer and Secretary of Immuneering Corp, was granted stock options for 110,000 shares on February 5, 2025.

Director Ann E. Berman acquired stock options in Immuneering Corp as part of the company's Non-Employee Director Compensation Program.

Director Peter Feinberg acquired stock options in Immuneering Corp in lieu of cash compensation.

Laurie Keating, a director at Immuneering Corp, acquired a stock option for 23,485 shares in lieu of a cash retainer, according to a Form 4 filing.

Mallory Morales, Chief Accounting Officer of Immuneering Corp, reports the acquisition of 4,458 shares of Class A Common Stock through the company's Employee Stock Purchase Plan at a price of $1.6235 per share.

Director Thomas J. Schall acquired stock options in Immuneering Corp on June 12, 2024.

Laurie Keating, a director at Immuneering Corp, acquired stock options for 33,350 shares of Class A Common Stock on June 12, 2024.

Robert J. Carpenter, a director of Immuneering Corp, acquired stock options for 33,350 shares of Class A Common Stock on June 12, 2024.